Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types
Authors:
- Pashtoon M. KasiPKPashtoon M. Kasi
- Jessica K. LeeJLJessica K. Lee
- Lincoln W. PasquinaLPLincoln W. Pasquina
- Brennan DeckerBDBrennan Decker
- Pierre Vanden BorrePBPierre Vanden Borre
- Dean C. PavlickDPDean C. Pavlick
- Justin M. AllenJAJustin M. Allen
- Christine ParachoniakCPChristine Parachoniak
- Julia C. F. QuintanilhaJQJulia C. F. Quintanilha
- Ryon P. GrafRGRyon P. Graf
- Alexa B. SchrockASAlexa B. Schrock
- Geoffrey R. OxnardGOGeoffrey R. Oxnard
Open Access
- 7 December 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (4) , 836-848
Abstract
Purpose: Genomic rearrangements can generate potent oncogenic drivers or disrupt tumor suppressor genes. This study examines the landscape of fusions and rearrangements detected by liquid biopsy (LBx) of circulating tumor DNA (ctDNA) across different cancer types. Experimental Design: LBx from 53,842 patients with 66 solid tumor types were profiled using FoundationOneLiquid CDx, a hybrid-capture sequencing platform that queries 324 cancer-related genes. Tissue biopsies (TBx) profiled using FoundationOneCDx were used as a comparator. Results: Among all LBx, 7,377 (14%) had ≥1 pathogenic rearrangement detected. A total of 3,648 (6.8%) LBx had ≥1 gain-of-function (GOF) oncogene rearrangement, and 4,428 (8.2%) LBx had ≥1 loss-of-function rearrangement detected. Cancer types with higher prevalence of GOF rearrangements included those with canonical fusion drivers: prostate cancer (19%), cholangiocarcinoma (6.4%), bladder (5.5%), and non–small cell lung cancer (4.4%). Although the prevalence of driver rearrangements was lower in LBx than TBx overall, the frequency of detection was comparable in LBx with a tumor fraction (TF) ≥1%. Rearrangements in FGFR2, BRAF, RET, and ALK, were detected across cancer types, but tended to be clonal variants in some cancer types and potential acquired resistance variants in others. Conclusions: In contrast to some prior literature, this study reports detection of a wide variety of rearrangements in ctDNA. The prevalence of driver rearrangements in tissue and LBx was comparable when TF ≥1%. LBx presents a viable alternative when TBx is not available, and there may be less value in confirmatory testing when TF is sufficient.Keywords
All Related Versions
Funding Information
- N/A
This publication has 57 references indexed in Scilit:
- Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancerOncotarget, 2016
- RING domain–deficient BRCA1 promotes PARP inhibitor and platinum resistanceJournal of Clinical Investigation, 2016
- The distribution of BRAF gene fusions in solid tumors and response to targeted therapyInternational Journal of Cancer, 2015
- BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK InhibitionClinical Cancer Research, 2013
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinomaHepatology, 2013
- Identification of Targetable FGFR Gene Fusions in Diverse CancersCancer Discovery, 2013
- Oncogenic FGFR3 gene fusions in bladder cancerHuman Molecular Genetics, 2012
- RET, ROS1 and ALK fusions in lung cancerNature Medicine, 2012
- Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutationBreast Cancer Research and Treatment, 2010